GSK - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.
Business & Industry
- GSK unveils Target the Future, a global, multi-year programme to help address key challenges affecting the multiple myeloma community
- Sanofi invests $180 million equity in Owkin's artificial intelligence and federated learning to advance oncology pipeline
- Pfizer and BioNTech receive expanded U.S. FDA emergency use suthorization of COVID-19 vaccine booster to include individuals 18 and older
- GSK and Vir Biotechnology announce United States government agreements to purchase sotrovimab, a COVID-19 treatment
- Pfizer to provide U.S. government with 10 million treatment courses of investigational oral antiviral candidate to help combat COVID-19
Research & Development
- Delaying second dose of mRNA COVID-19 vaccine produces stronger immune response
- ComCor study: New results on places of infection with SARS-CoV-2 and analysis of the efficacy of messenger RNA vaccines against the Delta variant
- WHO update on Omicron
- Targeted drug combination shows unprecedented activity in some highly aggressive brain tumors
- International Cancer Genome Consortium empowers cancer researchers everywhere with new cloud computing platform
- Aspirin is linked with increased risk of heart failure
- Exposure to harmless coronaviruses boosts SARS-CoV-2 immunity
Conferences & Events
- Modernise your Medical Affairs Insight Management with ViiV Healthcare, Eisai, ASC Therapeutics and Within3
- Novartis, Bayer and Boehringer Ingelheim to showcase their commitment to a reimagined pharma industry
- Scientists urge for investment now in highly potent vaccines to prevent the next pandemic
- CPhI Worldwide to return in 2021
- Reuters Events' Cell & Gene Therapy USA
- Total health: Build a better healthcare system
- Don't fall for the 'next best action' trap
Regulatory Affairs
- FDA authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in children 5 through 11 years of age
- FDA, NIH, and 15 private organizations join forces to increase effective gene therapies for rare diseases
- FDA takes additional actions on the use of a booster dose for COVID-19 vaccines
- FDA awards 11 grants to clinical trials to develop new medical products for rare disease treatments
- FDA approves innovative treatment for pediatric patients with congenital athymia